Moderna, Mexico to Produce Up to 10 Million COVID-19 Vaccine Doses
Moderna signed a long-term strategic agreement with Mexico to establish a local mRNA ecosystem and transfer technology to Laboratorios Liomont for domestic COVID-19 vaccine production, committing up to 10 million doses for the 2025-26 campaign. This partnership could boost key SPDR S&P Biotech ETF holdings through expanded vaccine output.
1. Strategic Agreement with Mexico
Moderna entered a long-term strategic agreement with the Mexican government to build a local mRNA ecosystem under the national 'Plan Mexico' initiative. The memorandum of understanding aims to support local clinical research, development programs, and pandemic preparedness frameworks based on Mexican health priorities.
2. Technology Transfer to Laboratorios Liomont
The deal secures technology transfer to Laboratorios Liomont for domestic manufacturing of Moderna’s COVID-19 vaccine. It includes a commitment to supply up to 10 million doses for Mexico’s 2025-26 vaccination campaign, strengthening local production capacity.
3. Implications for the Biotech ETF
Enhanced vaccine output in Mexico could benefit major holdings in the SPDR S&P Biotech ETF by diversifying manufacturing footprints and revenue streams across the biotech sector. The development underscores growing demand and potential revenue growth for mRNA-focused companies within the ETF.